Genital Herpes (GH), is a common sexually transmitted disease caused due to two viruses namely: herpes simplex virus 1 (HSV1) and herpes simplex virus 2 (HSV2) characterized by lifelong infection and periodic reactivation with no cure. Viruses penetrate the body through mucous membranes which line the openings of nose, mouth and genitalia.HSV1, HSV2 are found in body fluids of infected person.
Genital Herpes Market
The Genital Herpes market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Genital Herpes market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Genital Herpes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
According to Delveinsight, the United States accounts for the largest market size of Genital Herpes, in comparison to EU5 (United Kingdom, Spain, Italy, France, Spain) and Japan.
Among the EU5 countries, Germany has the highest market size, while the UK has the lowest market size of Genital Herpes in 2017.
Genital Herpes Epidemiology
The Genital Herpes epidemiology division provides insights about historical and current Genital Herpes patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Genital Herpes epidemiology part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
According to the Delveinsight, Genital Herpes is more prevalent among the females as compared to the males
Genital Herpes Drug Chapters
Drug chapter segment of the Genital Herpes report encloses the detailed analysis of Genital Herpes marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
It also helps to understand the Genital Herpes clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There are currently three FDA approved antiviral therapies including Acyclovir, Famciclovir and Valacyclovir, which are being used for the treatment of Genital herpes in the United States.
The dynamics of Genital Herpes market is anticipated to change during the forecasted period owing to the expected launch of emerging therapies and most awaited vaccines during the forecasted period of 2019–2028.
Some of the key companies in Genital Herpes Market includes:
-
Novartis
-
GlaxoSmithKline
-
Genocea Biosciences
-
AiCuris
-
Vical
About Delveinsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.